Integer (ITGR)
Market Price (11/1/2026): $126.585 | Market Cap: $4.3 BilSector: Health Care | Industry: Health Care Equipment
Integer (ITGR)
Market Price (11/1/2026): $126.585Market Cap: $4.3 BilSector: Health CareIndustry: Health Care Equipment
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Low stock price volatilityVol 12M is 32% Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, Precision Medicine, and Aging Population & Chronic Disease. Themes include Remote Patient Monitoring, Show more. | Trading close to highsDist 52W High is -0.1% Weak multi-year price returns2Y Excs Rtn is -33%, 3Y Excs Rtn is -2.6% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 31x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 24x, P/EPrice/Earnings or Price/(Net Income) is 42x Weak revenue growthRev Chg QQuarterly Revenue Change % is -3.9% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -3.0% Key risksITGR key risks include [1] high customer concentration, Show more. |
| Low stock price volatilityVol 12M is 32% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, Precision Medicine, and Aging Population & Chronic Disease. Themes include Remote Patient Monitoring, Show more. |
| Trading close to highsDist 52W High is -0.1% |
| Weak multi-year price returns2Y Excs Rtn is -33%, 3Y Excs Rtn is -2.6% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 31x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 24x, P/EPrice/Earnings or Price/(Net Income) is 42x |
| Weak revenue growthRev Chg QQuarterly Revenue Change % is -3.9% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -3.0% |
| Key risksITGR key risks include [1] high customer concentration, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 10/1/2026
Integer (ITGR) stock has gained about 5% since 7/31/2026 because of the following key factors:
1. The primary driver for Integer's stock appreciation was the announcement of its acquisition by KKR.
On August 3, 2026, Integer Holdings Corporation (ITGR) revealed a definitive agreement to be acquired by an affiliate of KKR in an all-cash transaction valued at approximately $5.7 billion. Under the terms, Integer stockholders are set to receive $127 per share, representing a significant premium of approximately 51.8% to the unaffected closing share price on April 29, 2026, and 28.8% to the 30-day volume-weighted average price (VWAP) as of July 31, 2026.
2. The progression of the KKR acquisition, including key approvals, reduced deal uncertainty.
Integer received early termination of the Hart-Scott-Rodino Antitrust Improvements Act waiting period on September 29, 2026, which was a crucial condition for the acquisition's completion. Following this, Integer's stockholders further solidified the deal by approving the merger agreement on October 21, 2026, with approximately 99.95% of votes cast in favor. These milestones increased confidence that the transaction, anticipated to close by year-end 2026, would proceed as planned.
Show more
Integer (ITGR) stock has gained about 5% since 7/31/2026 because of the following key factors:
1. The primary driver for Integer's stock appreciation was the announcement of its acquisition by KKR.
On August 3, 2026, Integer Holdings Corporation (ITGR) revealed a definitive agreement to be acquired by an affiliate of KKR in an all-cash transaction valued at approximately $5.7 billion. Under the terms, Integer stockholders are set to receive $127 per share, representing a significant premium of approximately 51.8% to the unaffected closing share price on April 29, 2026, and 28.8% to the 30-day volume-weighted average price (VWAP) as of July 31, 2026.
2. The progression of the KKR acquisition, including key approvals, reduced deal uncertainty.
Integer received early termination of the Hart-Scott-Rodino Antitrust Improvements Act waiting period on September 29, 2026, which was a crucial condition for the acquisition's completion. Following this, Integer's stockholders further solidified the deal by approving the merger agreement on October 21, 2026, with approximately 99.95% of votes cast in favor. These milestones increased confidence that the transaction, anticipated to close by year-end 2026, would proceed as planned.
Show more
Updated on 10/1/2026
Integer (ITGR) stock has gained about 5% since 7/31/2026 because of the following key factors:
1. The primary driver for Integer's stock appreciation was the announcement of its acquisition by KKR.
On August 3, 2026, Integer Holdings Corporation (ITGR) revealed a definitive agreement to be acquired by an affiliate of KKR in an all-cash transaction valued at approximately $5.7 billion. Under the terms, Integer stockholders are set to receive $127 per share, representing a significant premium of approximately 51.8% to the unaffected closing share price on April 29, 2026, and 28.8% to the 30-day volume-weighted average price (VWAP) as of July 31, 2026.
2. The progression of the KKR acquisition, including key approvals, reduced deal uncertainty.
Integer received early termination of the Hart-Scott-Rodino Antitrust Improvements Act waiting period on September 29, 2026, which was a crucial condition for the acquisition's completion. Following this, Integer's stockholders further solidified the deal by approving the merger agreement on October 21, 2026, with approximately 99.95% of votes cast in favor. These milestones increased confidence that the transaction, anticipated to close by year-end 2026, would proceed as planned.
3. Despite missing analyst expectations in its fiscal Q3 2026 earnings, the impending acquisition largely insulated the stock from significant negative impact.
For its fiscal Q3 2026, which ended on October 2, 2026, Integer reported adjusted earnings per share (EPS) of $1.34, missing the Zacks Consensus Estimate of $1.65 to $1.68 per share by 18.79% to 20.4%. Revenues for the quarter were $449.66 million to $450 million, also falling short of consensus estimates by 1.4% to 1.67% and marking a 3.9% year-on-year decline. Specifically, Cardio & Vascular sales decreased 5% due to previously communicated impacts from new Electrophysiology products. However, the ongoing acquisition process and the locked-in share price of $127 largely mitigated the negative market reaction to these financial misses.
Show less
Integer (ITGR) stock has gained about 5% since 7/31/2026 because of the following key factors:
1. The primary driver for Integer's stock appreciation was the announcement of its acquisition by KKR.
On August 3, 2026, Integer Holdings Corporation (ITGR) revealed a definitive agreement to be acquired by an affiliate of KKR in an all-cash transaction valued at approximately $5.7 billion. Under the terms, Integer stockholders are set to receive $127 per share, representing a significant premium of approximately 51.8% to the unaffected closing share price on April 29, 2026, and 28.8% to the 30-day volume-weighted average price (VWAP) as of July 31, 2026.
2. The progression of the KKR acquisition, including key approvals, reduced deal uncertainty.
Integer received early termination of the Hart-Scott-Rodino Antitrust Improvements Act waiting period on September 29, 2026, which was a crucial condition for the acquisition's completion. Following this, Integer's stockholders further solidified the deal by approving the merger agreement on October 21, 2026, with approximately 99.95% of votes cast in favor. These milestones increased confidence that the transaction, anticipated to close by year-end 2026, would proceed as planned.
3. Despite missing analyst expectations in its fiscal Q3 2026 earnings, the impending acquisition largely insulated the stock from significant negative impact.
For its fiscal Q3 2026, which ended on October 2, 2026, Integer reported adjusted earnings per share (EPS) of $1.34, missing the Zacks Consensus Estimate of $1.65 to $1.68 per share by 18.79% to 20.4%. Revenues for the quarter were $449.66 million to $450 million, also falling short of consensus estimates by 1.4% to 1.67% and marking a 3.9% year-on-year decline. Specifically, Cardio & Vascular sales decreased 5% due to previously communicated impacts from new Electrophysiology products. However, the ongoing acquisition process and the locked-in share price of $127 largely mitigated the negative market reaction to these financial misses.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The 4.4% change in ITGR stock from 7/31/2026 to 10/31/2026 was primarily driven by a 41.8% change in the company's P/E Multiple.| (LTM values as of) | 7312026 | 10312026 | Change |
|---|---|---|---|
| Stock Price ($) | 121.21 | 126.59 | 4.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,856 | 1,825 | -1.6% |
| Net Income Margin (%) | 7.6% | 5.7% | -25.7% |
| P/E Multiple | 29.3 | 41.5 | 41.8% |
| Shares Outstanding (Mil) | 34 | 34 | 0.7% |
| Cumulative Contribution | 4.4% |
Market Drivers
7/31/2026 to 10/31/2026| Return | Correlation | |
|---|---|---|
| ITGR | 4.4% | |
| Market (SPY) | 1.2% | 28.5% |
| Sector (XLV) | 13.7% | -5.5% |
Fundamental Drivers
The 43.0% change in ITGR stock from 4/30/2026 to 10/31/2026 was primarily driven by a 94.1% change in the company's P/E Multiple.| (LTM values as of) | 4302026 | 10312026 | Change |
|---|---|---|---|
| Stock Price ($) | 88.51 | 126.59 | 43.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,856 | 1,825 | -1.6% |
| Net Income Margin (%) | 7.6% | 5.7% | -25.7% |
| P/E Multiple | 21.4 | 41.5 | 94.1% |
| Shares Outstanding (Mil) | 34 | 34 | 0.7% |
| Cumulative Contribution | 43.0% |
Market Drivers
4/30/2026 to 10/31/2026| Return | Correlation | |
|---|---|---|
| ITGR | 43.0% | |
| Market (SPY) | 5.4% | 16.2% |
| Sector (XLV) | 27.2% | 8.6% |
Fundamental Drivers
The 96.1% change in ITGR stock from 10/31/2025 to 10/31/2026 was primarily driven by a 59.4% change in the company's P/E Multiple.| (LTM values as of) | 10312025 | 10312026 | Change |
|---|---|---|---|
| Stock Price ($) | 64.57 | 126.59 | 96.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,831 | 1,825 | -0.3% |
| Net Income Margin (%) | 4.7% | 5.7% | 19.7% |
| P/E Multiple | 26.1 | 41.5 | 59.4% |
| Shares Outstanding (Mil) | 35 | 34 | 3.1% |
| Cumulative Contribution | 96.1% |
Market Drivers
10/31/2025 to 10/31/2026| Return | Correlation | |
|---|---|---|
| ITGR | 96.1% | |
| Market (SPY) | 11.7% | 27.3% |
| Sector (XLV) | 29.8% | 19.0% |
Fundamental Drivers
The 56.0% change in ITGR stock from 10/31/2023 to 10/31/2026 was primarily driven by a 26.5% change in the company's P/E Multiple.| (LTM values as of) | 10312023 | 10312026 | Change |
|---|---|---|---|
| Stock Price ($) | 81.17 | 126.59 | 56.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,503 | 1,825 | 21.4% |
| Net Income Margin (%) | 5.5% | 5.7% | 3.6% |
| P/E Multiple | 32.8 | 41.5 | 26.5% |
| Shares Outstanding (Mil) | 33 | 34 | -2.0% |
| Cumulative Contribution | 56.0% |
Market Drivers
10/31/2023 to 10/31/2026| Return | Correlation | |
|---|---|---|
| ITGR | 56.0% | |
| Market (SPY) | 86.9% | 34.1% |
| Sector (XLV) | 55.5% | 26.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ITGR Return | 5% | -20% | 45% | 34% | -41% | 61% | 56% |
| Peers Return | 22% | 8% | 27% | 35% | 46% | 24% | 308% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 13% | 106% |
Monthly Win Rates [3] | |||||||
| ITGR Win Rate | 67% | 33% | 67% | 58% | 42% | 90% | |
| Peers Win Rate | 53% | 53% | 57% | 60% | 62% | 56% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| ITGR Max Drawdown | -20% | -42% | -26% | -15% | -56% | -7% | |
| Peers Max Drawdown | -18% | -25% | -23% | -20% | -29% | -38% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: JBL, FLEX, PLXS, SANM, MDT.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 10/30/2026 (YTD)
How Low Can It Go
| Event | ITGR | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -19.1% | -9.5% |
| % Gain to Breakeven | 23.5% | 10.5% |
| Time to Breakeven | 9 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -39.8% | -24.5% |
| % Gain to Breakeven | 66.2% | 32.4% |
| Time to Breakeven | 199 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -49.4% | -33.7% |
| % Gain to Breakeven | 97.5% | 50.9% |
| Time to Breakeven | 347 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -12.1% | -19.2% |
| % Gain to Breakeven | 13.8% | 23.8% |
| Time to Breakeven | 23 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -16.8% | -3.7% |
| % Gain to Breakeven | 20.2% | 3.9% |
| Time to Breakeven | 4 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -40.7% | -12.2% |
| % Gain to Breakeven | 68.7% | 13.9% |
| Time to Breakeven | 566 days | 62 days |
In The Past
Integer's stock fell -3.9% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 4.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | ITGR | S&P 500 |
|---|---|---|
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -39.8% | -24.5% |
| % Gain to Breakeven | 66.2% | 32.4% |
| Time to Breakeven | 199 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -49.4% | -33.7% |
| % Gain to Breakeven | 97.5% | 50.9% |
| Time to Breakeven | 347 days | 140 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -40.7% | -12.2% |
| % Gain to Breakeven | 68.7% | 13.9% |
| Time to Breakeven | 566 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -26.4% | -6.8% |
| % Gain to Breakeven | 35.8% | 7.3% |
| Time to Breakeven | 476 days | 15 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -29.4% | -17.9% |
| % Gain to Breakeven | 41.6% | 21.8% |
| Time to Breakeven | 479 days | 123 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -22.5% | -53.4% |
| % Gain to Breakeven | 29.0% | 114.4% |
| Time to Breakeven | 71 days | 1085 days |
In The Past
Integer's stock fell -3.9% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 4.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Integer (ITGR)
Integer Holdings Corporation (ITGR) operates as a significant medical device outsource manufacturer, predominantly serving the global healthcare industry. The company specializes in the design, development, and manufacturing of a comprehensive range of medical devices and components across numerous therapeutic areas. This includes critical products for interventional cardiology, structural heart, peripheral vascular, and neurovascular procedures, alongside cardiac rhythm management devices such as implantable pacemakers, defibrillators, and leads.
The company's offerings extend to advanced surgical tools for arthroscopic, laparoscopic, and general surgery, as well as orthopedic instruments utilized in hip, knee, and spine surgeries. Integer also produces essential components like non-rechargeable and rechargeable batteries, device enclosures, and lead sub-assemblies, which are vital for both implantable and portable medical technologies. Its primary customers in the medical segment are multi-national Original Equipment Manufacturers (OEMs) and their subsidiaries, who integrate Integer’s solutions into their branded medical products for markets including cardiac, neuromodulation, orthopedics, vascular, and advanced surgical.
Beyond its core medical device manufacturing, Integer leverages its specialized battery and power management expertise to serve non-medical markets. The company provides customized battery power and power management systems, as well as battery solutions, for specific applications within the energy, military, and environmental sectors. In essence, Integer is a crucial behind-the-scenes partner, enabling leading medical device companies with foundational components and finished devices, while also applying its technological capabilities to diverse industrial markets.
AI Analysis | Feedback
Here are 1-2 brief analogies for Integer (ITGR):
- Foxconn for critical medical device components.
- Qualcomm for specialized medical device hardware.
AI Analysis | Feedback
- Medical Device Components and Sub-assemblies: Manufactures specialized components like feedthroughs, device enclosures, and machined parts for a wide range of medical devices used in various procedures.
- Cardiac Rhythm Management Products: Produces implantable pacemakers, defibrillators, cardiac monitors, and associated leads for managing heart rhythm disorders.
- Neuromodulation Products: Offers implantable spinal cord stimulators designed for neurological applications.
- Advanced Surgical and Orthopedic Instruments: Develops instruments and components for arthroscopic, laparoscopic, general, hip, knee, and spine surgeries.
- Battery and Power Management Solutions: Provides non-rechargeable and rechargeable batteries, chargers, and custom power systems for medical, energy, military, and environmental markets.
AI Analysis | Feedback
Integer Holdings Corporation (ITGR) sells primarily to other companies. Its major customers are multi-national original equipment manufacturers (OEMs) and their affiliated subsidiaries in the cardiac, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets.
The background information provided does not list the specific names of these customer companies.
AI Analysis | Feedback
null
AI Analysis | Feedback
Payman Khales, President and Chief Executive Officer
Payman Khales assumed the role of President and Chief Executive Officer of Integer Holdings Corporation in October 2025, completing a planned leadership transition. He joined Integer in 2018 as President of the Cardio & Vascular business, where he led a strategy that reportedly doubled sales in seven years. Most recently, he served as Chief Operating Officer, overseeing both of Integer's business units and its global operations. Prior to joining Integer, Khales held senior leadership roles at CECO Environmental Corp. and Ingersoll Rand Company.
Diron Smith, Executive Vice President and Chief Financial Officer
Diron Smith was promoted to Executive Vice President and Chief Financial Officer of Integer Holdings Corporation in October 2023, after serving as interim CFO since May 2023. He joined Integer in August 2021 as Vice President of Financial Planning & Analysis. Smith brings 30 years of experience in financial leadership roles at public companies, including Tiffany & Co. and GE. At Tiffany & Co., he was VP and Finance Officer for the Americas region and later VP and Finance Officer for Global Supply and Distribution. His 15 years at General Electric included leadership positions in GE Energy Management, GE HealthCare, GE Water & Process Technology, and GE Fanuc Automation. He also served at eVisionUSA.com and KPMG.
Kirk Thor, Executive Vice President, Chief Human Resources Officer
Kirk Thor is the Executive Vice President and Chief Human Resources Officer at Integer, responsible for the company's enterprise-wide people strategy, communications, and human resources functions. He joined Integer in 2018 from Flowserve Corporation, where he was Vice President of Talent Management and Organization Development. His prior experience includes executive HR positions at JCPenney and Centex Corporation, and leadership roles at Walt Disney Parks and Resorts, National Data Corporation, and the U.S. Army Research Institute. Thor also consulted for the National Football League (NFL) for 16 years, assessing draft picks and predicting behavior in professional athletes.
Tommy P. Thomas, Vice President and Corporate Controller
Tommy P. Thomas serves as the Vice President and Corporate Controller of Integer Holdings Corporation. He was appointed to this role in February 2018. In April 2024, he sold 1,500 shares of common stock, adjusting his holdings in the company to 2,813 shares.
AI Analysis | Feedback
Integer Holdings Corporation (ITGR) faces several key risks inherent to its position as a medical device outsource manufacturer.
The most significant risks include:
Customer Concentration and Product Adoption Risk
Integer is highly dependent on a limited number of major original equipment manufacturer (OEM) customers, with its top three customers accounting for nearly half of its total sales in 2024. Any reduction in business from these key customers, or a slowdown in the market adoption and commercial uptake of their new products, can materially and disproportionately impact Integer's revenue and financial performance. Recent instances of weaker demand and slower rollouts of new products from key OEMs have directly contributed to challenges in Integer's financial guidance and stock underperformance. This reliance creates significant revenue volatility and execution risk, as Integer's substantial upfront investments in manufacturing capacity are predicated on customer forecasts that may not always align with actual market adoption.Regulatory and Compliance Risks
As a global medical device manufacturer, Integer operates within a highly regulated environment, subject to stringent requirements from bodies such as the FDA and other international regulatory agencies. Changes in these regulations, increased scrutiny, or failures to comply can lead to substantial costs, delays in product development and approval, product recalls, and reputational damage. For example, a tightening of the FDA's accelerated approval pathways, as seen in 2025, presents both opportunities and heightened regulatory risks for Integer's OEM customers and, by extension, for Integer itself.Supply Chain and Raw Material Risks
Integer relies on a continuous supply of various raw materials and components, often sourced from a limited number of third-party suppliers. Disruptions in the supply chain, geopolitical tensions, inflationary pressures, or fluctuations in the cost of these materials (including precious metals) can impact Integer's ability to manufacture products profitably and on schedule. The difficulty in quickly establishing additional or replacement suppliers for critical materials due to rigid requirements further exacerbates this risk.AI Analysis | Feedback
null
AI Analysis | Feedback
Integer Holdings Corporation (ITGR) operates in various medical device markets and also provides battery solutions for non-medical sectors. The addressable markets for its main products and services are sized globally and, where available, for North America, as follows:
- Cardiac Rhythm Management Devices: The global market size for cardiac rhythm management devices was estimated at USD 20.77 billion in 2024 and is projected to reach USD 36.19 billion by 2033. Another estimate places the global market at USD 23.87 billion in 2025, expected to grow to approximately USD 43.19 billion by 2035. North America is a significant region in this market, holding approximately 45.34% of the global revenue share in 2024.
- Neuromodulation Devices (including Spinal Cord Stimulators): The global neuromodulation devices market was estimated at USD 6.37 billion in 2025 and is projected to reach USD 13.93 billion by 2033. Another report estimates the global market at USD 8.11 billion in 2025, with a projection to reach around USD 27.15 billion by 2035. North America held the largest share, accounting for 43.37% of the global revenue in 2025.
- Interventional Cardiology Devices: This market was valued at USD 11.28 billion globally in 2025 and is projected to reach USD 19.75 billion by 2033. Other data suggests the global market size was USD 15.95 billion in 2025 and is predicted to increase to approximately USD 29.9 billion by 2034. North America held the largest global revenue share, at 44.91% in 2025.
- Peripheral Vascular Devices: The global peripheral vascular devices market size was estimated at USD 10.44 billion in 2024 and is projected to reach USD 16.90 billion by 2033. Another source indicates a global market size of USD 9.853.30 million in 2024, expected to grow to USD 15.544.32 million by 2032. North America dominated the global market with a revenue share of 38.92% in 2024.
- Surgical Equipment and General Surgery Devices (including Arthroscopic, Laparoscopic, and General Surgery Devices, and Electrocautery Components): The global surgical equipment market size was estimated at USD 18.37 billion in 2024 and is projected to reach USD 31.58 billion by 2030. Separately, the global electrosurgical devices market was USD 6.2 billion in 2025 and is projected to reach USD 10.2 billion by 2034. The global general surgery devices market size was calculated at USD 16.65 billion in 2025 and is predicted to increase to approximately USD 34.63 billion by 2034. North America held a significant share in these markets, for instance, dominating the surgical equipment market with a 40.31% revenue share in 2024.
- Orthopedic Devices and Instruments: The global orthopedic devices market size was valued at USD 65.28 billion in 2025 and is projected to grow to USD 105.45 billion by 2034. The global orthopedic surgical instrument market size was USD 60284.5 million (USD 60.28 billion) in 2024 and is expected to boost sales to USD 82038.87 million (USD 82.03 billion) by 2031. North America dominated the orthopedic devices market with a 54.92% market share in 2025.
- Medical Batteries: The global medical batteries market was valued at USD 2.0 billion in 2024 and is projected to advance to USD 2.7 billion by 2029. Another report indicates a market size of USD 1.74 billion in 2025, predicted to increase to approximately USD 2.91 billion by 2035. North America is expected to be the largest regional market for medical batteries.
- Industrial and Specialty Batteries (for energy, military, and environmental markets): The global industrial batteries market size is projected to grow from USD 21.2 billion in 2024 to USD 34.7 billion by 2029. Another estimate puts the global industrial batteries market at USD 22.44 billion in 2024, projected to reach USD 34.57 billion by 2030. The global specialty battery market size was valued at USD 2.97 billion in 2024 and is expected to be worth around USD 5.24 billion by 2034. Specifically for the military battery market, the size stood at USD 1.56 billion in 2025 and is projected to hit USD 1.97 billion by 2030. North America was a leading region in the specialty battery market, accounting for a 36.80% revenue share in 2024.
AI Analysis | Feedback
Integer Holdings Corporation (ITGR) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and market dynamics:
- Growth in High-Demand Medical Device Segments: Integer anticipates sustained revenue growth from its strong position and new product introductions within high-growth medical device markets. Specifically, areas such as electrophysiology, structural heart, neurovascular, peripheral vascular, and neuromodulation are identified as significant drivers. The Cardio & Vascular segment, in particular, has shown strong performance, supported by new product ramps and robust customer demand.
- Robust New Product Development and Launches: A strong and diversified product development pipeline is a critical component of Integer's long-term growth strategy. While some recently launched products may present temporary headwinds in 2026, the company is confident in its ability to return to above-market organic sales growth by 2027, driven by its ongoing innovation and new product introductions.
- Strategic Tuck-in Acquisitions: Integer continues to execute a strategy of targeted "tuck-in" acquisitions to enhance its capabilities and strengthen its market presence in key growth areas. Recent acquisitions, such as Precision Coating and VSi Parylene, have expanded the company's specialized service offerings and are expected to contribute to revenue growth.
- Operational Improvements and Capacity Expansion: Ongoing investments in manufacturing efficiencies and continuous improvement initiatives are expected to support revenue growth by optimizing Integer's existing operational footprint and enhancing its ability to meet increasing customer demand. These improvements, coupled with disciplined expense management, contribute to a stronger competitive position and capacity for growth.
AI Analysis | Feedback
Share Repurchases
- Integer's Board of Directors authorized a share repurchase program of up to $200 million in November 2025.
- In the fourth quarter of 2025, the company repurchased 698,356 common shares for $50 million.
- Integer intends to commence an accelerated share repurchase program (ASR) in early 2026 to repurchase approximately $50 million of common stock under its existing authorization.
Share Issuance
- In March 2025, Integer completed an offering of $1.0 billion aggregate principal amount of 1.875% convertible senior notes due 2030, with proceeds used to exchange existing convertible notes, repay borrowings, and purchase cap calls to minimize dilution.
- As part of the acquisition of VSi Parylene in February 2025, Integer issued $5 million in common stock as part of the total purchase consideration.
Outbound Investments
- Since 2021, Integer has invested over $700 million in tuck-in acquisitions to expand capabilities and presence in targeted markets.
- In the first quarter of fiscal year 2025, the company completed the strategic tuck-in acquisitions of Precision Coating for approximately $152 million and VSi Parylene for approximately $28 million.
- Integer completed the acquisition of Pulse Technologies in January 2024, enhancing its capabilities in precision micro machining and strengthening its pipeline in high-growth markets.
Capital Expenditures
- Since 2021, Integer has consistently invested in capital expenditures, amounting to 5.8% of sales.
- Capital expenditures were $91 million in fiscal year 2025.
- For fiscal year 2026, expected capital expenditures are projected to be between $95 million and $105 million, or approximately 5% to 6% of sales, primarily focused on enhancing technology capabilities, automation, and capacity.
Peer Outperformance in Health Care Equipment
ITGR has outperformed 86% of its 49 Health Care Equipment peers over 5Y. Health Care Equipment ranks 5th of 10 industries in Health Care by median 5Y return.
Share of Health Care Equipment constituents that ITGR has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
96%
of 54 industry peers · 96.1% return
3Y
70%
of 53 industry peers · 53.6% return
5Y
86%
of 49 industry peers · 40.6% return
No Health Care Equipment peer with a comparable growth profile has beaten ITGR by more than 20pp over 5Y.
Median price return by industry across the Health Care sector, ranked by 5Y. Health Care Equipment is ITGR's own industry. Use this to see which corners of the sector have carried the returns.
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 6 | 10.9% | 56.8% | 98.5% | CAH 480% · MCK 390% · COR 186% |
| Health Care Services | 20 | 33.8% | 44.0% | 12.4% | HIMS 255% · RDNT 136% · DGX 89% |
| Managed Health Care | 8 | 34.4% | -1.2% | -3.6% | OSCR 76% · HQY 55% · ELV 4% |
| Health Care Facilities | 25 | 12.1% | 18.2% | -5.4% | THC 281% · NHC 236% · EHC 182% |
| Health Care Equipment ← | 50 | 0.7% | 10.2% | -17.8% | GKOS 420% · UFPT 360% · PLSE 148% |
| Pharmaceuticals | 61 | -15.0% | 9.2% | -34.9% | LQDA 1102% · KNSA 788% · LLY 482% |
| Health Care Supplies | 11 | 15.5% | 2.3% | -39.9% | LNTH 329% · HAE 74% · MMSI 28% |
| Life Sciences Tools & Services | 107 | -8.1% | -1.9% | -66.4% | NTRA 262% · AXGN 225% · MEDP 188% |
| Biotechnology | 363 | -25.0% | -26.2% | -81.1% | DNTH 1187% · ELVN 1129% · TRVI 1054% |
| Health Care Technology | 21 | -23.8% | -48.9% | -82.4% | VEEV -1% · DOCS -53% |
Median of constituents with a full price history over each window. Top names are limited to companies above $2B market cap.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 145.79 |
| Mkt Cap | 18.6 |
| Rev LTM | 21,859 |
| Op Inc LTM | 1,148 |
| FCF LTM | 689 |
| FCF 3Y Avg | 728 |
| CFO LTM | 1,256 |
| CFO 3Y Avg | 1,112 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 15.9% |
| Rev Chg 3Y Avg | 5.4% |
| Rev Chg Q | 26.5% |
| QoQ Delta Rev Chg LTM | 6.2% |
| Op Inc Chg LTM | 16.8% |
| Op Inc Chg 3Y Avg | 6.1% |
| Op Mgn LTM | 5.3% |
| Op Mgn 3Y Avg | 5.0% |
| QoQ Delta Op Mgn LTM | 0.0% |
| CFO/Rev LTM | 6.3% |
| CFO/Rev 3Y Avg | 6.3% |
| FCF/Rev LTM | 4.2% |
| FCF/Rev 3Y Avg | 4.2% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 18.6 |
| P/S | 1.1 |
| P/Op Inc | 18.6 |
| P/EBIT | 18.8 |
| P/E | 29.3 |
| P/CFO | 17.6 |
| Total Yield | 3.4% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 5.4% |
| D/E | 0.2 |
| Net D/E | 0.1 |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cardio & Vascular | 1,107 | 950 | 836 | 699 | |
| Cardiac Rhythm Management & Neuromodulation | 669 | 661 | 613 | 534 | |
| Other Markets | 78 | 106 | 106 | ||
| Advanced Surgical, Orthopedics & Portable Medical | 98 | ||||
| Medical | 1,183 | ||||
| Non-Medical | 38 | ||||
| Total | 1,854 | 1,717 | 1,556 | 1,331 | 1,221 |
| $ Mil | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Medical | 270 | 206 | 214 | 169 | 224 |
| Non-Medical | 3 | 8 | 8 | 5 | 16 |
| Unallocated operating expenses | -105 | -92 | -86 | -54 | -83 |
| Total | 167 | 121 | 136 | 121 | 158 |
| $ Mil | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Medical | 2,807 | 2,652 | 2,448 | 2,212 | 2,234 |
| Unallocated assets | 81 | 85 | 78 | 107 | 69 |
| Non-Medical | 54 | 57 | 56 | 53 | 51 |
| Total | 2,943 | 2,794 | 2,582 | 2,372 | 2,353 |
Price Behavior
Price Behavior
| Market Price | $126.59 | |
| Market Cap ($ Bil) | 4.3 | |
| First Trading Date | 09/29/2000 | |
| Distance from 52W High | -0.1% | |
| 50 Days | 200 Days | |
| DMA Price | $126.20 | $100.81 |
| DMA Trend | up | up |
| Distance from DMA | 0.3% | 25.6% |
| 3M | 1YR | |
| Volatility | 3.2% | 32.0% |
| Downside Capture | -5.15 | 18.25 |
| Upside Capture | 19.68 | 95.24 |
| Correlation (S&P 500) | 13.3% | 28.8% |
ITGR Betas & Captures as of 10/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.01 | 0.02 | 0.16 | 0.49 | 0.68 | 0.78 |
| Up Beta | 0.00 | 0.10 | 0.58 | 0.29 | 0.87 | 0.91 |
| Down Beta | 0.01 | -0.00 | 0.04 | 0.75 | 0.81 | 0.74 |
| Up Capture | 3% | 5% | 18% | 88% | 93% | 40% |
| Bmk +ve Days | 12 | 18 | 28 | 62 | 130 | 427 |
| Stock +ve Days | 11 | 22 | 32 | 72 | 142 | 399 |
| Down Capture | -0% | -4% | -6% | -16% | 19% | 88% |
| Bmk -ve Days | 10 | 25 | 36 | 64 | 121 | 325 |
| Stock -ve Days | 9 | 19 | 30 | 52 | 107 | 349 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ITGR | |
|---|---|---|---|---|
| ITGR | 94.4% | 32.0% | 2.09 | - |
| Sector ETF (XLV) | 30.2% | 16.4% | 1.41 | 18.8% |
| Equity (SPY) | 10.9% | 12.8% | 0.52 | 28.1% |
| Gold (GLD) | -2.0% | 28.6% | -0.08 | 4.4% |
| Commodities (DBC) | 48.2% | 20.6% | 1.79 | -11.3% |
| Real Estate (VNQ) | 10.2% | 13.7% | 0.45 | 21.8% |
| Bitcoin (BTCUSD) | -30.0% | 43.5% | -0.70 | -5.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ITGR | |
|---|---|---|---|---|
| ITGR | 7.4% | 35.2% | 0.28 | - |
| Sector ETF (XLV) | 8.7% | 15.3% | 0.37 | 35.2% |
| Equity (SPY) | 12.2% | 17.1% | 0.53 | 41.9% |
| Gold (GLD) | 16.2% | 19.0% | 0.68 | 4.7% |
| Commodities (DBC) | 9.2% | 19.5% | 0.35 | 0.9% |
| Real Estate (VNQ) | 0.9% | 18.9% | -0.06 | 40.6% |
| Bitcoin (BTCUSD) | 4.9% | 51.6% | 0.28 | 15.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ITGR | |
|---|---|---|---|---|
| ITGR | 21.1% | 38.0% | 0.62 | - |
| Sector ETF (XLV) | 12.0% | 16.8% | 0.59 | 46.5% |
| Equity (SPY) | 15.2% | 17.9% | 0.72 | 52.2% |
| Gold (GLD) | 11.4% | 16.5% | 0.56 | 1.3% |
| Commodities (DBC) | 8.2% | 18.1% | 0.37 | 14.0% |
| Real Estate (VNQ) | 5.3% | 20.7% | 0.21 | 48.2% |
| Bitcoin (BTCUSD) | 61.8% | 66.2% | 1.02 | 9.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 11/1/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 10/29/2026 | -0.0% | ||
| 8/3/2026 | 2.7% | 3.3% | 3.3% |
| 4/30/2026 | 5.8% | 3.1% | 6.8% |
| 2/19/2026 | -4.0% | 0.0% | -2.5% |
| 10/23/2025 | -32.3% | -40.2% | -37.6% |
| 7/24/2025 | -7.5% | -6.1% | -7.7% |
| 4/24/2025 | 0.8% | 4.8% | -2.0% |
| 2/20/2025 | -5.6% | -11.8% | -18.8% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 13 | 13 | 8 |
| # Negative | 11 | 10 | 15 |
| Median Positive | 2.7% | 3.1% | 7.9% |
| Median Negative | -5.0% | -5.1% | -5.3% |
| Max Positive | 15.6% | 18.7% | 29.0% |
| Max Negative | -32.3% | -40.2% | -37.6% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 10/29/2026 | -0.0% | ||
| 8/3/2026 | 2.7% | 3.3% | 3.3% |
| 4/30/2026 | 5.8% | 3.1% | 6.8% |
| 2/19/2026 | -4.0% | 0.0% | -2.5% |
| 10/23/2025 | -32.3% | -40.2% | -37.6% |
| 7/24/2025 | -7.5% | -6.1% | -7.7% |
| 4/24/2025 | 0.8% | 4.8% | -2.0% |
| 2/20/2025 | -5.6% | -11.8% | -18.8% |
| 10/24/2024 | 0.2% | 2.7% | 7.4% |
| 7/25/2024 | -7.1% | -4.6% | -0.7% |
| 4/25/2024 | -9.8% | -10.9% | -1.2% |
| 2/15/2024 | -5.0% | -4.6% | 8.3% |
| 10/26/2023 | 15.6% | 18.7% | 29.0% |
| 7/27/2023 | 7.2% | 6.2% | -5.3% |
| 4/27/2023 | 5.7% | 0.0% | -1.4% |
| 2/16/2023 | 3.7% | 2.6% | 1.4% |
| 10/27/2022 | 2.1% | 3.6% | 20.0% |
| 7/28/2022 | -0.3% | 1.9% | -0.9% |
| 4/28/2022 | -0.0% | 0.3% | -0.4% |
| 2/17/2022 | 0.3% | -2.4% | -7.2% |
| 10/28/2021 | 1.0% | -0.6% | -9.0% |
| 7/29/2021 | 0.9% | -5.6% | -5.4% |
| 4/29/2021 | -0.8% | -2.0% | -5.8% |
| 2/18/2021 | 7.9% | 14.1% | 15.1% |
| SUMMARY STATS | |||
| # Positive | 13 | 13 | 8 |
| # Negative | 11 | 10 | 15 |
| Median Positive | 2.7% | 3.1% | 7.9% |
| Median Negative | -5.0% | -5.1% | -5.3% |
| Max Positive | 15.6% | 18.7% | 29.0% |
| Max Negative | -32.3% | -40.2% | -37.6% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2026 | 10/29/2026 | 10-Q |
| 06/30/2026 | 08/04/2026 | 10-Q |
| 03/31/2026 | 04/30/2026 | 10-Q |
| 12/31/2025 | 02/23/2026 | 10-K |
| 09/30/2025 | 10/23/2025 | 10-Q |
| 06/30/2025 | 07/24/2025 | 10-Q |
| 03/31/2025 | 04/24/2025 | 10-Q |
| 12/31/2024 | 02/20/2025 | 10-K |
| 09/30/2024 | 10/24/2024 | 10-Q |
| 06/30/2024 | 07/25/2024 | 10-Q |
| 03/31/2024 | 04/25/2024 | 10-Q |
| 12/31/2023 | 02/20/2024 | 10-K |
| 09/30/2023 | 10/26/2023 | 10-Q |
| 06/30/2023 | 07/27/2023 | 10-Q |
| 03/31/2023 | 04/27/2023 | 10-Q |
| 12/31/2022 | 02/21/2023 | 10-K |
| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2026 | 10/29/2026 | 10-Q |
| 06/30/2026 | 08/04/2026 | 10-Q |
| 03/31/2026 | 04/30/2026 | 10-Q |
| 12/31/2025 | 02/23/2026 | 10-K |
| 09/30/2025 | 10/23/2025 | 10-Q |
| 06/30/2025 | 07/24/2025 | 10-Q |
| 03/31/2025 | 04/24/2025 | 10-Q |
| 12/31/2024 | 02/20/2025 | 10-K |
| 09/30/2024 | 10/24/2024 | 10-Q |
| 06/30/2024 | 07/25/2024 | 10-Q |
| 03/31/2024 | 04/25/2024 | 10-Q |
| 12/31/2023 | 02/20/2024 | 10-K |
| 09/30/2023 | 10/26/2023 | 10-Q |
| 06/30/2023 | 07/27/2023 | 10-Q |
| 03/31/2023 | 04/27/2023 | 10-Q |
| 12/31/2022 | 02/21/2023 | 10-K |
| 09/30/2022 | 10/27/2022 | 10-Q |
| 06/30/2022 | 07/28/2022 | 10-Q |
| 03/31/2022 | 04/28/2022 | 10-Q |
| 12/31/2021 | 02/22/2022 | 10-K |
| 09/30/2021 | 10/28/2021 | 10-Q |
| 06/30/2021 | 07/29/2021 | 10-Q |
| 03/31/2021 | 04/29/2021 | 10-Q |
| 12/31/2020 | 02/18/2021 | 10-K |
| 09/30/2020 | 10/29/2020 | 10-Q |
| 06/30/2020 | 07/30/2020 | 10-Q |
| 03/31/2020 | 05/08/2020 | 10-Q |
| 12/31/2019 | 02/20/2020 | 10-K |
Insider Activity
Updated 10/26/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Thor, Kirk K | Chief Human Resources Officer | Direct | Sell | 9162026 | 126.23 | 11,767 | 1,485,295 | 902,891 | Form |
| 2 | Thor, Kirk K | Chief Human Resources Officer | Direct | Sell | 9162026 | 126.25 | 19,773 | 2,496,430 | 2,388,735 | Form |
| 3 | Senn, Andrew | President, Growth & Innovation | Direct | Sell | 9102026 | 126.30 | 9,408 | 1,188,230 | 682,652 | Form |
| 4 | Thomas, Tommy P | VP, Corporate Controller | Direct | Sell | 3172026 | 85.00 | 825 | 70,125 | 372,385 | Form |
| 5 | Harris, John A | EVP, Global Ops and Manufactur | Direct | Buy | 11132025 | 70.00 | 1,650 | 115,500 | 424,620 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Thor, Kirk K | Chief Human Resources Officer | Direct | Sell | 9162026 | 126.23 | 11,767 | 1,485,295 | 902,891 | Form |
| 2 | Thor, Kirk K | Chief Human Resources Officer | Direct | Sell | 9162026 | 126.25 | 19,773 | 2,496,430 | 2,388,735 | Form |
| 3 | Senn, Andrew | President, Growth & Innovation | Direct | Sell | 9102026 | 126.30 | 9,408 | 1,188,230 | 682,652 | Form |
| 4 | Thomas, Tommy P | VP, Corporate Controller | Direct | Sell | 3172026 | 85.00 | 825 | 70,125 | 372,385 | Form |
| 5 | Harris, John A | EVP, Global Ops and Manufactur | Direct | Buy | 11132025 | 70.00 | 1,650 | 115,500 | 424,620 | Form |
| 6 | Thomas, Tommy P | VP, Corporate Controller | Direct | Sell | 11132025 | 70.15 | 884 | 62,013 | 252,259 | Form |
| 7 | Smith, Diron | EVP, Chief Financial Officer | Direct | Buy | 11102025 | 67.19 | 1,116 | 74,967 | 517,179 | Form |
| 8 | Capps, Cheryl C | Direct | Buy | 11102025 | 66.70 | 1,600 | 106,720 | 780,523 | Form | |
| 9 | Khales, Payman | President & CEO | Direct | Buy | 10302025 | 64.94 | 3,127 | 203,067 | 1,484,853 | Form |
Investor Activity (13F)
Updated Nov 1, 202613F holdings as of Mar 31, 2026 (Q1 2026)
Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 10/31/2026